Breaking News: For many breast cancer survivors, a common treatment might be unnecessary. This is a huge shift in how we understand post-mastectomy care! An international study suggests that radiotherapy, often used after a mastectomy, may not be needed for a significant number of patients.
The research reveals that women with early-stage breast cancer who underwent a mastectomy – the surgical removal of the breast – experienced similar survival rates over a 10-year period, regardless of whether they received radiotherapy. This is based on the results of the SUPREMO trial, a collaborative effort involving researchers from various countries.
For years, chest wall radiotherapy has been a standard practice following mastectomy for many patients with early-stage breast cancer. The aim was to eliminate any remaining cancer cells and lower the risk of recurrence. But here's where it gets controversial: This practice was largely based on trials from the 1980s, which are now considered outdated. This has led to uncertainty about its benefits and variations in its use worldwide.
The SUPREMO trial, spearheaded by the University of Edinburgh, focused on patients at intermediate risk of breast cancer recurrence. This group included women from 17 countries who had between one and three affected lymph nodes, as well as those with no affected nodes but other aggressive tumor characteristics. All 1,607 participants underwent mastectomy, axillary surgery (removal of lymph nodes from the armpit), and modern anti-cancer therapy. They were then randomly assigned to receive either chest wall radiotherapy (808 women) or no radiotherapy (799 women).
The results? After a decade of follow-up, there was virtually no difference in overall survival. Approximately 81.4% of those who received radiotherapy were still alive, compared to 81.9% of those who did not. The study also found that radiotherapy had no impact on disease-free survival or on the spread of cancer.
Radiotherapy did have a minimal impact on cancer recurrence at the mastectomy site. Only 9 patients who received the treatment saw their breast cancer return on the chest wall, compared to 20 who did not. Furthermore, side effects from radiotherapy were mild, with no excess deaths reported from cardiac causes.
But this isn't the whole story. Experts believe the reduced benefit of radiotherapy is due to advancements in cancer treatments, especially improved drug therapies, which continue to reduce the chances of cancer returning and boost survival rates.
Important Note: The researchers caution that the study only included those with intermediate-risk breast cancer. Patients with a higher risk of recurrence might still benefit from chest wall radiotherapy.
The study is published in the New England Journal of Medicine. The research team included scientists from the UK, Netherlands, Australia, and China. It was funded by a partnership between the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), along with other organizations.
Professor Ian Kunkler from the University of Edinburgh stated, "The SUPREMO trial provides no evidence to support the continued use of radiotherapy to the area of the chest wall in most patients with intermediate-risk breast cancer who have undergone a mastectomy if they are also treated with modern anti-cancer drug treatment."
Dr. Nicola Russell from the Netherlands Cancer Institute added, "Although reported toxicity in the trial was mild, we know that almost all patients experience some side effects of radiotherapy, that can even develop even some years after treatment. Avoiding unnecessary irradiation will reduce both treatment burden and, for example, the detrimental effects on breast reconstruction for these mastectomy patients."
This research could lead to significant changes in how breast cancer is treated. The findings could allow patients to avoid unnecessary treatments, leading to more efficient use of healthcare resources. The trial also highlights the importance of collaboration and public funding in answering critical clinical questions.
What do you think? Does this study change your understanding of breast cancer treatment? Are you surprised by these findings, or do they align with your expectations? Share your thoughts in the comments below!
